Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jason Karp

Page 1 of 2

While the S&P 500 has slowed down this year after a sizzling three-year run, it seems that Jason Karp‘s Tourbillon Capital Partners and its 40 picks with a market cap of over $1 billion are not faltering in the least. Our extensive database and analytical tools, which covers over 700 of the most prominent hedge fund managers, says that Jason Karp’s above-mentioned positions could have made someone 9.16% in the second quarter alone, while we’ve calculated his 2015 returns through June 30 at an even more impressive 20.9%. Note that our weighted average returns metric is only an approximation of a fund’s returns from its long positions in stocks with at least $1 billion market caps, and does not factor in investments in smaller companies, short positions, or options, so they may differ greatly from a fund’s actual returns.

Jason Karp - Tourbillon Capital Partners

The returns might look shocking for someone who doesn’t know who Karp is, but of little surprise to those in the know, after he successfully served as co-chief investment officer at Carlson Capital LP and was the director of research and a money manager of global equities at CR Intrinsic Investors before launching his own long-short fund in 2013. According to its latest 13F filing, Tourbillon Capital is largely focused on the services sector, in which 37.98% of the value of holdings in its public equity portfolio was invested, while technology stocks were next at 20.13%. In our opinion, the outstanding performance of Tourbillon Capital Partners and the stocks behind it should not stay unnoticed by the general public, therefore in this article we are going to review several large, well-performing holdings in the portfolio of the hedge fund manager, including Expedia Inc (NASDAQ:EXPE), Inc (NASDAQ:AMZNand Horizon Pharma PLC (NASDAQ:HZNP).

Jason Karp
Jason Karp
Tourbillon Capital Partners

We don’t just track the latest moves of funds. We are, in fact, more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds we track. We gather and share this information based on 16 years of research, with backtests for the period between 1999 and 2012 and forward testing for the last 2.5 years. The results of our analysis show that these 15 most popular small-cap picks have a great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month in backtests. Moreover, since the beginning of forward testing in August 2012, the strategy worked brilliantly, outperforming the market every year and returning 135%, which is more than 80 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

Following a hike of 352%, the total position of Tourbillion Capital Partners in Expedia Inc (NASDAQ:EXPE) included 3.43 million shares worth $322.87 million at the end of March. Over the second quarter of the year, the stock of the $13.77 billion online travel company appreciated by 14.70%, realizing the best expectations of Jason Karp (or so we imagine). At the beginning of 2015, Expedia announced its plans to acquire another online booking service, Orbitz Worldwide Inc (NYSE:OWW) for $12.00 per share in cash. The deal was approved by shareholders in May, and the merged company will control around 75% of the US market and 5-6% of the global travel market, which significantly expands its profitability potential. Among the other prominent hedge funds that we follow, Paul Reeder and Edward Shapiro‘s PAR Capital Management held some 3.66 million shares, valued at $344.5 million, leading the list of top investors in Expedia Inc (NASDAQ:EXPE).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!